25 Sep 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250925857310/en/Anebulo-Pharmaceuticals-Announces-First-Patients-Dosed-in-Phase-1-Single-Ascending-Dose-Study-of-Intravenous-Selonabant-under-Development-for-Acute-Cannabis-Induced-Toxicity
23 Dec 2024
// BUSINESSWIRE